{"disease":{"id":"mesothelioma","name":"Mesothelioma","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for mesothelioma has evolved with the approval of immunotherapy combinations, such as nivolumab and ipilimumab, which have become a first-line standard of care. Platinum-pemetrexed based chemotherapy remains an option. Several agents are in development, including targeted therapies and novel immunotherapies, aiming to improve outcomes and address unmet needs, particularly in later lines of therapy. Clinical trials play a crucial role in advancing treatment options.","drug_count":7,"description":"Mesothelioma is a rare and aggressive cancer primarily affecting the mesothelial cells of the pleura (lining of the lungs), peritoneum (lining of the abdomen), or pericardium (lining of the heart). It is strongly associated with asbestos exposure. Treatment options are limited, and the prognosis is generally poor, but recent advances in immunotherapy have improved outcomes.","subtype_count":12},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.943Z","updated_at":"2026-03-25T12:16:34.943Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":79,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":null,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"pemetrexed-disodium","indication_name":"Malignant Pleural Mesothelioma - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed","indication_name":"Malignant mesothelioma of pleura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alimta","generic_name":"pemetrexed","company_name":"Actavis","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"Folate Analog Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Alimta works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division."},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed-dipotassium","indication_name":"Initial treatment of malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DIPOTASSIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog Metabolic Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"pemetrexe","indication_name":"Malignant mesothelioma of pleura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pemetrexe","company_name":"Rongjie Tao","drug_phase":"marketed","molecular_target":"Serine hydroxymethyltransferase, cytosolic, Folate receptor beta, Folate transporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Malignant Pleural Mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06996249","title":"Prospective Data Collection Initiative on Thoracic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Dutch Society of Physicians for Pulmonology and Tuberculosis","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT05910112","title":"Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT00242723","title":"Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","phase":"","overall_status":"RECRUITING","enrollment_count":1310,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03830229","title":"Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01950572","title":"Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT06097728","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":825,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04431024","title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT00128102","title":"Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":661,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02899299","title":"Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT01843374","title":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":571,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT01907100","title":"Nintedanib (BIBF 1120) in Mesothelioma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":545,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02214134","title":"SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access","phase":"","overall_status":"COMPLETED","enrollment_count":539,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT02784171","title":"Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":true},{"nct_id":"NCT04792463","title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mohamed Abdel-Rahman","has_results":false},{"nct_id":"NCT05042557","title":"Real World Study of MPM in China","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT04665206","title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":434,"lead_sponsor_name":"Vivace Therapeutics, Inc","has_results":false},{"nct_id":"NCT02349412","title":"Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03762018","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT07330271","title":"PTC-Guided Therapy for Peritoneal Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":347,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03063450","title":"CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"University of Southampton","has_results":false},{"nct_id":"NCT06503146","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT07449624","title":"From Presentation to Diagnosis: Patterns of Pleural Effusion","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Mansoura University Hospital","has_results":false},{"nct_id":"NCT05193006","title":"Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT01851395","title":"Rapid Autopsy and Procurement of Cancer Tissue","phase":"","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT02903914","title":"Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06535607","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02709512","title":"Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Polaris Group","has_results":true},{"nct_id":"NCT02610140","title":"Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03683680","title":"Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT06581549","title":"Immune Microenvironment and Gene Expression Profiling in Mesothelioma","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT04334759","title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"PrECOG, LLC.","has_results":false},{"nct_id":"NCT05308966","title":"Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Groupe Francais De Pneumo-Cancerologie","has_results":false},{"nct_id":"NCT02385812","title":"Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04631731","title":"Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Western Sydney Local Health District","has_results":false},{"nct_id":"NCT04843007","title":"Alvopem® (Pemetrexed) Safety Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"NanoAlvand","has_results":true},{"nct_id":"NCT05278975","title":"Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"RS Oncology LLC","has_results":false},{"nct_id":"NCT03654833","title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}